Condition
Autoimmunity, Inflammation
Total Trials
1
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Secukinumab
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
100%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 4 (1)
Trial Status
Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Secukinumab1
Active Sponsors
- Novartis Pharma AG1
- Novartis Pharmaceuticals1
Related Conditions
- Psoriatic Arthritis Ankylosing Spondylitis Nonradiographic Axial Spondyloarthritis Severe Chronic Plaque Psoriasis Moderate To Severe Chronic Plaque Psoriasis Juvenile Idiopathic Arthritis1